Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study-Reference-Cited by-同舟云学术

Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

Published:2019-01-11 Issue:8 Volume:60 Page:1972-1977
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Awan Farrukh T.¹^ORCID,Thirman Michael J.²,Patel-Donnelly Dipti³,Assouline Sarit⁴,Rao Arati V.⁵,Ye Wei⁵,Hill Brian⁶,Sharman Jeff P.⁷

Affiliation:

1. Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA;

2. Department of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA;

3. Virginia Cancer Specialists, Fairfax, VA, USA;

4. Department of Oncology, McGill University Medical School, Montreal, QC, Canada;

5. Gilead Sciences, Inc., Foster City, CA, USA;

6. Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA;

7. Willamette Valley Cancer Institute and Research Center and US Oncology Research, Springfield, OR, USA

Funder

Gilead Sciences, Inc

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1562180

Reference27 articles.

1. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

2. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

3. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

4. The efficacy of ibrutinib in the treatment of Richter syndrome

5. Ibrutinib has some activity in Richter’s syndrome

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019–2023);Future Medicinal Chemistry;2024-08-27

2. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08

3. B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia;Frontiers in Oncology;2024-02-26

4. Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors;Haematologica;2024-01-18

5. The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis;Frontiers in Immunology;2023-12-04